Clinical Trial

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated March 20, 2024 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a phase II/III, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with docetaxel/ HB1801 in Patients with Squamous cell non-small cell lung cancer （sqNSCLC）.
Trial Details
NCT Number NCT06319313
Lead Sponsor Shanghai JMT-Bio Inc.
Conditions Squamous Cell Non-small Cell Lung Cancer
Enrollment 534 participants
Start Date 2024-05-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-03-20